Aurinia Pharmaceuticals (AUPH) announced that Kevin Tang, Aurinia’s Chair of the Board, will succeed Peter Greenleaf as Chief Executive Officer. Peter will continue as a consultant to facilitate the transition. Aurinia also has appointed Ryan Cole as Chief Operating Officer, Michael Hearne as Chief Financial Officer and Thomas Wei as Chief Scientific Officer. Stew Kroll and Stephen Robertson will continue in their roles as Chief Development Officer and General Counsel, respectively.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUPH:
- Aurinia Pharmaceuticals Earnings Call Highlights Growth And Risks
- Aurinia Lifts Profits on LUPKYNIS Growth and Sets Double-Digit 2026 Revenue Outlook
- Aurinia Lifts Revenue on LUPKYNIS Growth, Sets Strong 2026 Sales Outlook
- Aurinia Pharmaceuticals reports Q4 EPS $1.53, consensus 22c
- Aurinia Pharmaceuticals sees 2026 revenue $315M-$-325M, consensus $326.8M